Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Conditions: Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma Interventions: Biological: LioCyx-M; Drug: Lenvatinib Sponsor: Lion TCR Pte. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials